Patrik Dahlen is the New CEO of Immudex

The Board of Directors of Immudex A/S has appointed Mr. Patrik Dahlen as the new Chief Executive Officer (CEO) of Immudex A/S. He will start in his new position 1 November 2022. Former CEO Helene K. Hjenner will continue to be active in the operation of Immudex A/S to ensure a smooth transition following which Helene will take part in the overall strategic management of Immudex A/S as a new member of the Board of Directors.

"I wish success to Patrik, and I am confident that he, together with the management team and personnel, will continue the development of Immudex and successful implementation of its strategy. At the same time, on the behalf of the majority shareholders and the Board of Directors, I thank Helene for her work for Immudex and all the many fruitful achievements that she has accomplished together with the Immudex team in the transition of Immudex from startup to well-established company", says majority shareholder Viggo Harboe.

“As a member of the Board of Directors I have been closely following the development of Immudex operations during the past years. Now I am happy to take on CEO position of the Company with respect of the achievements and direction already set by management. Together with the management team and personnel we will further strengthen and develop efficient operations and double-digit growth. Our strength is working together to develop and deliver high quality products to our customers, which is even more important in this current economic and market situation. I would like to thank the Board of Directors for the trust, and for my part, Helene, for her valuable work for the Company”, says new CEO Patrik Dahlen.

"The past six years at Immudex have been an eventful and amazing experience. We have come a long way and I would like to thank my colleagues, the board and all partners and stakeholders for the support and cooperation. I wish Patrik and the Company the best of success and look forward to continuing my contribution to the success of Immudex as a member of the Board of Directors" says Helene K. Hjenner.

About Immudex

Immudex ApS is a pioneering life science company and the trusted partner of scientists worldwide spearheading the global adoption of precision cellular immune monitoring. Immudex’s mission is to help researchers and clinicians unravel the complexity of the immune system, enabling the development of more effective immune-based therapeutics and diagnostics.

Immudex operates globally, with headquarters in Copenhagen, Denmark, and North American operations based in Fairfax, Virginia. Immudex’s Dextramer® technology is superior for the detection of antigen-specific immune cells, including rare and low-affinity cells. Immudex offers a broad product portfolio that allows scientists to investigate diverse types of immune cells, including T cells, non-conventional T cells and B cells, with reagents tailored to specific applications. Immudex’s products are compatible with multiple platforms from flow cytometry to next generation sequencing and single-cell multi-omics.

In addition to Dextramer® reagents for basic research, Immudex also provides Clinical-Grade Dextramer® (GMP) products and Dextramer® CMV Kits (IVD) manufactured in ISO 13485:2106-certified facilities, according to the requirements of FDA QSR 21 CFR 820. Immudex’s products enable scientists to get the full picture of the immune response, supporting ground-breaking advances within immuno-oncology, transplantation, autoimmune and infectious diseases.